SCHEMBL10247230

SCHEMBL10247230

Cc1ccc(-c2cc(C(=O)N[C@H]3CCCc4cc(C(=O)NO)ccc43)[nH]n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
TNF P01375 1/20 0.45
NOD1 Q9Y239 1/20 0.45
ALPL P05186 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
TAS1R3 Q7RTX0 3/20 0.44
TAS1R1 Q7RTX1 3/20 0.44
KDM5B Q9UGL1 1/20 0.44
HDAC8 Q9BY41 2/20 0.43
MAPK8 P45983 1/20 0.43
DHODH Q02127 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10247022 1.00 LMNA (0.48) LMNATNFNOD1ALPLPOLB
SCHEMBL10247071 0.91 HDAC8 (0.52) LMNATNFNOD1ALPLTAS1R3
SCHEMBL10249731 0.91 HDAC8 (0.52) LMNATNFNOD1ALPLTAS1R3
SCHEMBL10246997 0.84 LMNA (0.62) LMNATAS1R3TAS1R1DHODHKMT2A
SCHEMBL10246902 0.81 KMT2A (0.48) LMNAPOLBTAS1R3TAS1R1KMT2A
SCHEMBL10246951 0.78 LMNA (0.51) LMNAPOLBTAS1R3TAS1R1KMT2A
SCHEMBL10247155 0.78 LMNA (0.77) LMNARAB9ATAS1R3TAS1R1HDAC8
SCHEMBL10246933 0.77 DHODH (0.53) LMNAPOLBTAS1R3TAS1R1DHODH
SCHEMBL10252064 0.76 TAS1R3 (0.49) LMNAPOLBTAS1R3TAS1R1KMT2A
SCHEMBL10249684 0.75 HTT (0.62) LMNATAS1R3TAS1R1HDAC8KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012322-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 LMNA 1529/4885TNF 1042/4885NOD1 4213/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 LMNA 2546/4885TNF 1173/4885NOD1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.